CN1156287C - A pharmaceutical composition for treating myocardial diseases - Google Patents
A pharmaceutical composition for treating myocardial diseases Download PDFInfo
- Publication number
- CN1156287C CN1156287C CNB001315161A CN00131516A CN1156287C CN 1156287 C CN1156287 C CN 1156287C CN B001315161 A CNB001315161 A CN B001315161A CN 00131516 A CN00131516 A CN 00131516A CN 1156287 C CN1156287 C CN 1156287C
- Authority
- CN
- China
- Prior art keywords
- treatment
- pharmaceutical composition
- cardiomyopathy
- olibanum
- myrrha
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Fee Related
Links
- 208000031229 Cardiomyopathies Diseases 0.000 title claims abstract description 19
- 239000008194 pharmaceutical composition Substances 0.000 title claims abstract description 15
- 239000004863 Frankincense Substances 0.000 claims abstract description 17
- 241000180649 Panax notoginseng Species 0.000 claims abstract description 14
- 235000003143 Panax notoginseng Nutrition 0.000 claims abstract description 14
- 244000153234 Hibiscus abelmoschus Species 0.000 claims abstract description 13
- 241001489978 Eupolyphaga Species 0.000 claims abstract description 12
- 238000000034 method Methods 0.000 claims abstract description 11
- 239000000284 extract Substances 0.000 claims abstract description 9
- RYGMFSIKBFXOCR-UHFFFAOYSA-N Copper Chemical compound [Cu] RYGMFSIKBFXOCR-UHFFFAOYSA-N 0.000 claims abstract description 7
- 229910052802 copper Inorganic materials 0.000 claims abstract description 7
- 239000010949 copper Substances 0.000 claims abstract description 7
- 239000000843 powder Substances 0.000 claims abstract description 7
- 239000000341 volatile oil Substances 0.000 claims abstract description 7
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims abstract description 6
- 238000001914 filtration Methods 0.000 claims abstract description 4
- 241000717739 Boswellia sacra Species 0.000 claims description 15
- 241001057584 Myrrha Species 0.000 claims description 15
- 238000002360 preparation method Methods 0.000 claims description 15
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 claims description 12
- 238000005516 engineering process Methods 0.000 claims description 12
- 239000002775 capsule Substances 0.000 claims description 8
- 239000012141 concentrate Substances 0.000 claims description 6
- 239000003208 petroleum Substances 0.000 claims description 6
- 239000008187 granular material Substances 0.000 claims description 5
- 239000004615 ingredient Substances 0.000 claims description 4
- 230000001954 sterilising effect Effects 0.000 claims description 4
- 238000004659 sterilization and disinfection Methods 0.000 claims description 4
- 238000004090 dissolution Methods 0.000 claims description 3
- 238000000227 grinding Methods 0.000 claims description 3
- 239000002904 solvent Substances 0.000 claims description 3
- 240000007594 Oryza sativa Species 0.000 claims description 2
- 235000007164 Oryza sativa Nutrition 0.000 claims description 2
- 230000008569 process Effects 0.000 claims description 2
- 238000010791 quenching Methods 0.000 claims description 2
- 235000009566 rice Nutrition 0.000 claims description 2
- 235000021419 vinegar Nutrition 0.000 claims description 2
- 239000000052 vinegar Substances 0.000 claims description 2
- 239000002994 raw material Substances 0.000 claims 2
- 239000002552 dosage form Substances 0.000 claims 1
- 238000001035 drying Methods 0.000 claims 1
- 230000000171 quenching effect Effects 0.000 claims 1
- 230000000694 effects Effects 0.000 abstract description 15
- 230000001737 promoting effect Effects 0.000 abstract description 7
- 230000017531 blood circulation Effects 0.000 abstract description 4
- 206010047470 viral myocarditis Diseases 0.000 abstract description 4
- 230000003680 myocardial damage Effects 0.000 abstract description 3
- 230000002107 myocardial effect Effects 0.000 abstract description 3
- 238000012545 processing Methods 0.000 abstract description 3
- 238000005728 strengthening Methods 0.000 abstract description 3
- 230000017423 tissue regeneration Effects 0.000 abstract description 3
- 230000003915 cell function Effects 0.000 abstract description 2
- 230000004089 microcirculation Effects 0.000 abstract description 2
- 230000003647 oxidation Effects 0.000 abstract description 2
- 238000007254 oxidation reaction Methods 0.000 abstract description 2
- 230000008439 repair process Effects 0.000 abstract description 2
- 230000001502 supplementing effect Effects 0.000 abstract description 2
- 230000000451 tissue damage Effects 0.000 abstract description 2
- 231100000827 tissue damage Toxicity 0.000 abstract description 2
- 235000003717 Boswellia sacra Nutrition 0.000 abstract 2
- 240000007551 Boswellia serrata Species 0.000 abstract 2
- 235000012035 Boswellia serrata Nutrition 0.000 abstract 2
- 240000007311 Commiphora myrrha Species 0.000 abstract 2
- 235000006965 Commiphora myrrha Nutrition 0.000 abstract 2
- 235000007265 Myrrhis odorata Nutrition 0.000 abstract 2
- 241000131329 Carabidae Species 0.000 abstract 1
- 241000402754 Erythranthe moschata Species 0.000 abstract 1
- 240000005373 Panax quinquefolius Species 0.000 abstract 1
- 235000003140 Panax quinquefolius Nutrition 0.000 abstract 1
- 230000002159 abnormal effect Effects 0.000 abstract 1
- 210000000988 bone and bone Anatomy 0.000 abstract 1
- 150000002632 lipids Chemical class 0.000 abstract 1
- 238000011084 recovery Methods 0.000 abstract 1
- 229940126680 traditional chinese medicines Drugs 0.000 abstract 1
- 239000003814 drug Substances 0.000 description 7
- 239000000049 pigment Substances 0.000 description 7
- 210000004369 blood Anatomy 0.000 description 6
- 239000008280 blood Substances 0.000 description 6
- 239000000203 mixture Substances 0.000 description 6
- 208000024891 symptom Diseases 0.000 description 6
- 206010008479 Chest Pain Diseases 0.000 description 5
- 206010056370 Congestive cardiomyopathy Diseases 0.000 description 5
- 206010011703 Cyanosis Diseases 0.000 description 5
- 201000010046 Dilated cardiomyopathy Diseases 0.000 description 5
- 208000009525 Myocarditis Diseases 0.000 description 5
- 206010030113 Oedema Diseases 0.000 description 5
- 244000269722 Thea sinensis Species 0.000 description 4
- 230000006378 damage Effects 0.000 description 4
- 201000010099 disease Diseases 0.000 description 4
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 4
- 210000004165 myocardium Anatomy 0.000 description 4
- 241000699670 Mus sp. Species 0.000 description 3
- 208000019622 heart disease Diseases 0.000 description 3
- 230000001225 therapeutic effect Effects 0.000 description 3
- 102000004420 Creatine Kinase Human genes 0.000 description 2
- 108010042126 Creatine kinase Proteins 0.000 description 2
- 208000029549 Muscle injury Diseases 0.000 description 2
- 239000004480 active ingredient Substances 0.000 description 2
- 230000008859 change Effects 0.000 description 2
- 208000029078 coronary artery disease Diseases 0.000 description 2
- 230000000857 drug effect Effects 0.000 description 2
- 238000000605 extraction Methods 0.000 description 2
- 238000005469 granulation Methods 0.000 description 2
- 230000003179 granulation Effects 0.000 description 2
- 230000006872 improvement Effects 0.000 description 2
- 210000003734 kidney Anatomy 0.000 description 2
- JVTAAEKCZFNVCJ-UHFFFAOYSA-N lactic acid Chemical compound CC(O)C(O)=O JVTAAEKCZFNVCJ-UHFFFAOYSA-N 0.000 description 2
- 210000004185 liver Anatomy 0.000 description 2
- 238000011160 research Methods 0.000 description 2
- 238000007873 sieving Methods 0.000 description 2
- 102000004625 Aspartate Aminotransferases Human genes 0.000 description 1
- 108010003415 Aspartate Aminotransferases Proteins 0.000 description 1
- 208000019838 Blood disease Diseases 0.000 description 1
- 206010049993 Cardiac death Diseases 0.000 description 1
- 208000020446 Cardiac disease Diseases 0.000 description 1
- 206010011906 Death Diseases 0.000 description 1
- 101710088194 Dehydrogenase Proteins 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- 208000015220 Febrile disease Diseases 0.000 description 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
- 206010019280 Heart failures Diseases 0.000 description 1
- 206010020772 Hypertension Diseases 0.000 description 1
- 102000014150 Interferons Human genes 0.000 description 1
- 108010050904 Interferons Proteins 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- 241000699666 Mus <mouse, genus> Species 0.000 description 1
- 206010067482 No adverse event Diseases 0.000 description 1
- 206010042434 Sudden death Diseases 0.000 description 1
- 206010047513 Vision blurred Diseases 0.000 description 1
- 208000027418 Wounds and injury Diseases 0.000 description 1
- 230000000202 analgesic effect Effects 0.000 description 1
- 238000004458 analytical method Methods 0.000 description 1
- 230000003110 anti-inflammatory effect Effects 0.000 description 1
- 230000006907 apoptotic process Effects 0.000 description 1
- 206010003119 arrhythmia Diseases 0.000 description 1
- 230000006793 arrhythmia Effects 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- WHGYBXFWUBPSRW-FOUAGVGXSA-N beta-cyclodextrin Chemical compound OC[C@H]([C@H]([C@@H]([C@H]1O)O)O[C@H]2O[C@@H]([C@@H](O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O3)[C@H](O)[C@H]2O)CO)O[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@@H]3O[C@@H]1CO WHGYBXFWUBPSRW-FOUAGVGXSA-N 0.000 description 1
- 238000009534 blood test Methods 0.000 description 1
- 210000001124 body fluid Anatomy 0.000 description 1
- 239000010839 body fluid Substances 0.000 description 1
- 230000003683 cardiac damage Effects 0.000 description 1
- 210000004027 cell Anatomy 0.000 description 1
- 230000003833 cell viability Effects 0.000 description 1
- 238000006243 chemical reaction Methods 0.000 description 1
- 230000008602 contraction Effects 0.000 description 1
- 230000008878 coupling Effects 0.000 description 1
- 238000010168 coupling process Methods 0.000 description 1
- 238000005859 coupling reaction Methods 0.000 description 1
- 230000034994 death Effects 0.000 description 1
- 230000007812 deficiency Effects 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 230000018109 developmental process Effects 0.000 description 1
- 238000009826 distribution Methods 0.000 description 1
- 208000002173 dizziness Diseases 0.000 description 1
- 239000000890 drug combination Substances 0.000 description 1
- 238000009472 formulation Methods 0.000 description 1
- 210000001035 gastrointestinal tract Anatomy 0.000 description 1
- 239000008103 glucose Substances 0.000 description 1
- 238000009499 grossing Methods 0.000 description 1
- 208000014951 hematologic disease Diseases 0.000 description 1
- 208000018706 hematopoietic system disease Diseases 0.000 description 1
- 230000023597 hemostasis Effects 0.000 description 1
- 235000008216 herbs Nutrition 0.000 description 1
- 229960003444 immunosuppressant agent Drugs 0.000 description 1
- 230000001861 immunosuppressant effect Effects 0.000 description 1
- 239000003018 immunosuppressive agent Substances 0.000 description 1
- 208000014674 injury Diseases 0.000 description 1
- 229940079322 interferon Drugs 0.000 description 1
- 150000002500 ions Chemical class 0.000 description 1
- 235000014655 lactic acid Nutrition 0.000 description 1
- 239000004310 lactic acid Substances 0.000 description 1
- 210000000265 leukocyte Anatomy 0.000 description 1
- 230000007774 longterm Effects 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 231100000682 maximum tolerated dose Toxicity 0.000 description 1
- 230000002503 metabolic effect Effects 0.000 description 1
- 239000004570 mortar (masonry) Substances 0.000 description 1
- 210000003205 muscle Anatomy 0.000 description 1
- 208000031225 myocardial ischemia Diseases 0.000 description 1
- 208000002089 myocardial stunning Diseases 0.000 description 1
- 210000000107 myocyte Anatomy 0.000 description 1
- 230000001717 pathogenic effect Effects 0.000 description 1
- 238000011197 physicochemical method Methods 0.000 description 1
- 238000003825 pressing Methods 0.000 description 1
- 230000003449 preventive effect Effects 0.000 description 1
- 208000037920 primary disease Diseases 0.000 description 1
- 230000001681 protective effect Effects 0.000 description 1
- 150000003254 radicals Chemical class 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 230000029058 respiratory gaseous exchange Effects 0.000 description 1
- 230000000638 stimulation Effects 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
- 235000015961 tonic Nutrition 0.000 description 1
- 230000001256 tonic effect Effects 0.000 description 1
- 229960000716 tonics Drugs 0.000 description 1
- 239000011573 trace mineral Substances 0.000 description 1
- 235000013619 trace mineral Nutrition 0.000 description 1
- 238000012546 transfer Methods 0.000 description 1
- 208000012949 viral dilated cardiomyopathy Diseases 0.000 description 1
- 230000000007 visual effect Effects 0.000 description 1
Landscapes
- Medicines Containing Plant Substances (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Abstract
The invention relates to the field of traditional Chinese medicines, in particular to a pharmaceutical composition for treating myocardial diseases. Is prepared from notoginseng, musk, American ginseng, frankincense, myrrh, ground beetle, dragon bone, native copper, etc. through extracting volatile oil from frankincense and myrrh, collecting and processing into extractum; collecting Eupolyphaga Seu Steleophaga extractive solution, and processing into extract; decocting Os Draconis water soluble component for several times, filtering, and concentrating into extract; mixing the prepared extract with ground Moschus, and sterilized fine powders of Notoginseng radix and radix Panacis Quinquefolii. The invention combines the methods of supplementing qi and nourishing yin, strengthening body resistance and eliminating evil and the like for treating viral myocarditis with the methods of promoting blood circulation and promoting tissue regeneration, treating stasis and dredging collaterals for treating myocardial damage, can improve microcirculation, repair tissue damage, stabilize cell function, resist lipid oxidation and promote the functional recovery of abnormal myocardial cells, has reasonable formula ratio and obvious curative effect, and has good treatment and protection effects on myocardial diseases.
Description
The present invention relates to field of medicaments, especially a kind of pharmaceutical composition for the treatment of cardiomyopathy.
According to researching and analysing, in numerous heart disease patient, the viral myocarditis patient occupies the ratio of quite a few, and the trend that rises is day by day arranged, and its clinical manifestation weight differs, and heart failure can appear in weight person, seriously arrhythmia can occur, even sudden death.And its state of an illness is a DCM (dilated cardiomyopathy) at latency development also, and great majority are dead in 5 years subsequently.According to Abelman report, 0.71% cardiac death is arranged owing to the primary cardiac disease in the U.S., and in whole primary cardiac diseases, DCM (dilated cardiomyopathy) accounts for 90%.At present, still lack the medicine of better curative effect both at home and abroad for the treatment of primary disease, still adopt treatment meanss such as up-to-date immunosuppressant and interferon mostly; Having with Radix Panacis Quinquefolii, Moschus, Radix Notoginseng between the domestic people treat is the myocarditic report of composition treatment by Chinese herbs, but does not also find the preferable formulation components of curative effect, and its preparation technology also remains further to be studied.With modern medicine the degree of concern of hypertension, coronary heart disease is compared with the research dynamics, to myocarditis and the myocardiac research degree of depth, awareness, prevent and treat method and aspects such as long term follow-up and preventive measure also exist very big gap.
The object of the present invention is to provide a kind of from muscle-derived damage, promote injury repairing myocyte functional rehabilitation, reasonable component formula, curative effect preferably Chinese medicine control the pharmaceutical composition that the heart is treated the flesh disease.
Another object of the present invention is to provide the preparation of drug combination technology of the described treatment cardiomyopathy that a kind of technology is simple, flow process short, the effective ingredient extraction ratio is high.
Purpose of the present invention can realize by following measure:
A kind of pharmaceutical composition for the treatment of cardiomyopathy, be to form: Radix Notoginseng 35-40%, Moschus 1-2%, Radix Panacis Quinquefolii 15-20%, Olibanum 8-12%, Myrrha 8-12%, Eupolyphaga Seu Steleophaga 8-2%, Os Draconis 8-12%, Pyritum 8-12% by following components in weight percentage, its preparation technology contains following steps: (1) extracts the volatile oil of Olibanum, Myrrha, and with beta-schardinger dextrin-(β-CD) inclusion is fixed, and collects post-treatment and becomes extractum standby; (2) preparation Eupolyphaga Seu Steleophaga extracting solution, collect the percolate post-treatment and become extractum standby: (3) repeatedly take water soluble ingredient and filtrations such as Os Draconis, and reconcentration becomes extractum standby; (4) preparation nature powdered copper concentrate; (5) Moschus after prepared extractum, natural powdered copper concentrate and the grinding is mixed and can make with the Radix Notoginseng of sterilization, Western pure extract powder.Obtained mixture can make capsule through the granulation of sieving, dry in the shade, granulate, plug-in mounting.
Described Olibanum, Myrrha extraction process are as follows: Olibanum, Myrrha are ground into granule, do dissolution with solvents and be extracted into the colourless petroleum ether that in the water-bath ventilating kitchen, volatilizees again with petroleum ether, promptly get volatile oil, again with beta-schardinger dextrin-(β-CD) mixed inclusion to fix; The processing technique of described Pyritum is: get Pyritum and place inherent being fired to more than 560 ℃ of crucible to be popular in, quench shortcake once in the impouring rice vinegar immediately then, each about 2 hours for several times so repeatedly, until the gloss complete obiteration, airing was placed on and adds water in the mortar repeatedly and be ground to impalpable powder and use again.
The present invention has following advantage compared to existing technology:
The present invention understands systematicly myocarditis and myocardiac Chinese medicine again from this new visual field of myocardial damage and angle comprehensively, to treat the supplementing QI and nourishing YIN of viral myocarditis, methods and the promoting blood circulation for tissue regeneration for the treatment of the cardiac muscle damage such as strengthening vital QI to eliminate pathogenic factors, control the blood stasis and smoothing collaterals method and combine, but microcirculation improvement, the repair tissue damage, the stabilized cell function, the oxidation of lipotropism matter, promote parafunctional myocardial cell functional rehabilitation, and can transfer the fat the turbid descending, improve cell viability and ion and normally shift distribution, to free radical damage, cardiac muscle is to pressing down myocardial hibernation, non-hat metabolic cardiac damage, the emerging contraction coupling of cardiac muscle, situations such as apoptosis all have some improvement.Prescription reasonable mixture ratio of the present invention is evident in efficacy.Cardiomyopathy there are good curing and protective action.
Preparation technology's uniqueness of the present invention, the two lifting manipulations of pharmaceutically active ingredient are extracted in will adopting the volatile oil in the Olibanum Myrrha in the component, and it is consummate in order to active ingredient with the inclusion method, thereby reduce the gastrointestinal tract pessimal stimulation, alleviate or eliminate the untoward reaction of medicine, strengthen drug effect and curative effect, pure product fine powder is utilized not damage curative effect, do not pollute, and with not insulting physico-chemical method to component in addition sterilization handle, utilize above-mentioned prepared Pyritum, make its trace element component help human body and curative effect performance thereof, water solublity such as Os Draconis are extracted composition be condensed into extractum, make capsule again, guaranteed medicine quality and curative effect.
Drug effect theory of the present invention is as follows:
Radix Panacis Quinquefolii in the component of the present invention has the effect of YIN nourishing and the production of body fluid promoting, can be used for deficiency of both QI and YIN, the medical treatment of the disease of consumption of YIN caused by febrile disease; Radix Notoginseng has blood circulation promoting and blood stasis dispelling, the treating blood disorders of enriching blood hemostasis, anti-inflammatory analgesic, the effect of strengthening by means of tonics defying age is used for physical weakness, insufficiency of vital energy and blood, dizziness and blurred vision, mend through weak better effect arranged, and Eupolyphaga Seu Steleophaga, combinations such as Moschus, Os Draconis have the effect of blood circulation and promoting silt tissue regeneration promoting detumescence, can recuperate under medical treatment in the cardiac muscle damage.
Maximum tolerance determination result of the present invention is as follows:
20 of mices, male and female half and half, disposable ig60% suspension 0.4ml/10g of the present invention (animal capable tolerates the dose of Cmax and maximum volume), observe the mice active situation then and have or not death, continue 7 days, find that the mice ordinary circumstance is good, feed is normal, fur is bright and clean, and so none dead mouse is Ld
50Can't measure; Its maximum tolerated dose is 24g/kg, is equivalent to about 400 times of clinical application amount, is very safe so the present invention uses.
The present invention is through clinical use treatment myocarditis and dilated cardiomyopathy checking, and the result is as follows:
Viral myocarditis and dilated cardiomyopathy group patient amount to 77 examples, man's 22 examples, woman's 55 examples, myocarditis 65 examples, cardiomyopathy 12 examples, serious symptom person's 17 examples, middle disease person 59 examples, light disease person 1 example, through the present invention's treatment, observe cardiopalmus, uncomfortable in chest, chest pain, breathe hard, the degree of seven symptoms before and after treatment such as weak, cyanosis, edema with lapse to.Wherein the severity of symptom branch attach most importance to (+++), in (++), light (+), do not have (-) grade, its result such as following table:
Symptom integral lapses to comparison before and after myocarditis and the qtd of cardiomyopathy group treatment
Observe by stages
Cardiopalmus Uncomfortable in chest Chest pain Breathe hard
+++ ++ + - +++ ++ + - +++ ++ + - +++ ++ + -
Treat preceding 25.97 70.13 3.90 0.00 23.38 63.63 12.99 0.00 7.79 57.15 19.48 15.58 36.36 63.64 0.00 0.00
One week 2.60 57.14 36.36 3.90 2.60 46.75 44.16 6.49 0.00 44.16 37.66 18.18 3.90 58.44 27.27 10.39 of treatment
Two weeks 0.00 45.36 41.56 12.99 0.00 32.47 40.26 27.27 0.00 32.47 27.27 40.46 0.00 42.86 45.45 11.69 of treatment
Three weeks 0.00 32.48 33.76 0.00 0.00 28.58 25.97 45.45 0.00 27.27 19.48 53.25 0.00 28.57 40.26 31.17 of treatment
The treatment around 0.00 28.57 24.67 46.75 0.00 25.97 14.29 53.74 0.00 25.97 11.69 62.34 0.00 29.87 24.66 45.45
Continuous table
Observe by stages
Weak Cyanosis Edema
+++ ++ + - +++ ++ + - +++ ++ + -
Treat preceding 42.86 51.95 5.19 0.00 12.99 40.26 29.87 16.88 14.29 36.36 36.36 12.99
One week 7.79 59.74 28.57 3.90 6.49 33.77 27.27 32.47 3.90 35.06 22.08 38.96 of treatment
Two weeks 1.30 50.65 29.87 18.18 1.30 38.96 16.88 42.86 0.00 33.76 12.99 53.25 of treatment
Three weeks 0.00 36.36 32.47 31.17 0.00 33.77 16.88 49.35 0.00 35.06 10.39 54.55 of treatment
The treatment around 0.00 32.47 25.97 41.56 0.00 29.87 15.58 54.55 0.00 32.47 6.49 61.04
After with the present invention 4 week treatment, cardiopalmus, uncomfortable in chest, chest pain, breathe hard, seven symptoms such as weak, cyanosis, edema obviously reduce, produce effects person's 25 examples after the statistical result, responder's 52 examples, total effective rate reaches 100%.And after the treatment, the contrast myocardial enzymes the analysis showed that, shows that index lactic acid dehydrogenase (LDH), creatine phosphokinase (CK), the glutamic oxaloacetic transaminase, GOT (GOT) of myocardial damage all has obvious reduction; In addition, Liver and kidney merit and change of blood sugar and routine blood test change contrast before and after the treatment after measured, and the present invention is to Liver and kidney merit and blood glucose and pigment (Hb) total white blood cells and classify and all have no adverse effects.
For investigating the therapeutic effect of the present invention to myocardial ischemia (coronary heart disease), compare through clinical treatment and with commercially available tea pigment capsule and XUESHUANXINMAINING therapeutic effect and to do contrast, wherein of the present invention group of 57 examples, tea pigment capsule group 41 examples, XUESHUANXINMAINING group 38 examples, still observe cardiopalmus, uncomfortable in chest, chest pain, breathe hard, the degree of seven symptoms before and after treatment such as weak, cyanosis, edema with lapse to result such as following table (of the present invention group of 2-tea pigment capsule of 1-group 3-XUESHUANXINMAINING group)
The group n cardiopalmus course of treatment (%) (%) (%) uncomfortable in chest weak (%) chest pain (%) cyanosis (%) edema (%) of breathing hard
Treat preceding 1 57 116 (100) 127 (100) 126 (100) 129 (100) 75 (100) 88 (100) 93 (100)
2 41 85(100) 92(100) 92(100) 99(100) 48(100) 60(100) 57(100)
3 38 94(100) 65(100) 66(100) 84(100) 55(100) 43(100) 56(100)
One week 1 57 83 (71.55) 89 (70.08) 80 (63.49) 104 (80.62) 35 (46.67) 67 (76.14) 64 (68.82) of treatment
2 41 74(87.06)?65(70.65)?59(64.13)?79(79.80)?35(72.91)?55(91.67)?49(85.96)
3 38 73(77.66)?45(69.23)?42(63.64)?69(82.14)?38(64.09)?37(86.05)?41(73.21)
Two weeks 1 57 56 (48.28) 76 (59.84) 60 (47.62) 87 (73.44) 28 (37.33) 50 (56.82) 41 (44.09) of treatment
2 41 53(62.35)?68(73.91)?61(66.30)?84(84.85)?23(47.92)?44(73.33)?33(57.89)
3 38 57(60.64)?41(64.61)?34(51.51)?59(70.24)?27(49.04)?33(76.74)?32(57.14)
Three weeks 1 57 41 (35.34) 53 (41.73) 41 (32.54) 70 (54.26) 13 (17.33) 36 (40.91) 27 (29.03) of treatment
2 41 40(47.06)?59(64.13)?46(50.00)?65(65.66)?12(25.00)?29(48.33)?25(43.86)
3 38 39(41.49)?32(50.00)?25(37.88)?51(60.71)?15(27.27)?26(60.47)?22(39.29)
The treatment around 1 57 23 (19.83) 30 (23.62) 22 (17.46) 53 (41.08) 8 (10.67) 27 (30.68) 15 (16.13)
2 41 27(31.76)?44(47.83)?30(32.61)?60(60.61)?6(12.50) 26(43.33)?19(33.33)
3 38 31(32.98)?19(29.23)?15(22.72)?44(52.38)?11(20.00)?19(44.19)?14(25.00)
The present invention and tea pigment, XUESHUANXINMAINING efficacy result are relatively
Group produce effects enabledisable total effective rate
Of the present invention group 57.89% (33) 38.60% (22) 3.51% (2) 96.49% (55)
Tea pigment group 26.83% (11) 63.41% (26) 9.76% (4) 90.24% (37)
XUESHUANXINMAINING group 42.11% (16) 50.00% (19) 7.89% (3) 92.11% (35)
The result shows that of the present invention group of effective percentage is higher than tea pigment capsule group and XUESHUANXINMAINING group, and inefficiency is also lower, i.e. the present invention has therapeutical effect preferably.
The present invention also will be further described in conjunction with the embodiments:
One one kinds of pharmaceutical compositions for the treatment of cardiomyopathy of embodiment are to form by following components in weight percentage: Radix Notoginseng 35% Moschus 1% Radix Panacis Quinquefolii 19% Olibanum 9%
Myrrha 9% Eupolyphaga Seu Steleophaga 8% Os Draconis 11% Pyritum 8%
Its preparation technology is:＜1〉will get described group component Olibanum, Myrrha is ground into granule, do dissolution with solvents and be extracted into the colourless petroleum ether that in the water-bath ventilating kitchen, volatilizees again with petroleum ether, promptly get volatile oil, and (β-CD) inclusion is fixed, and collects post-treatment and becomes extractum standby with beta-schardinger dextrin-; (2) preparation Eupolyphaga Seu Steleophaga extracting solution, collect the percolate post-treatment and become extractum standby: (3) repeatedly take water soluble ingredient and filtrations such as Os Draconis, and reconcentration becomes extractum standby; (4) preparation nature powdered copper concentrate; (5) Moschus after prepared extractum, natural powdered copper concentrate and the grinding is mixed and can make with the Radix Notoginseng of sterilization, Western pure extract powder.Obtained mixture can make capsule through the granulation of sieving, dry in the shade, granulate, plug-in mounting.
21 kinds of pharmaceutical compositions for the treatment of cardiomyopathy of embodiment are to form by following components in weight percentage: Radix Notoginseng 39%, Moschus 1%, Radix Panacis Quinquefolii 16%, Olibanum 8%, Myrrha 10%, Eupolyphaga Seu Steleophaga 9%, Os Draconis 8%, Pyritum 9%.Its preparation technology is identical with embodiment one.
31 kinds of pharmaceutical compositions for the treatment of cardiomyopathy of embodiment are to form by following components in weight percentage: Radix Notoginseng 36%, Moschus 2%, Radix Panacis Quinquefolii 18%, Olibanum 9%, Myrrha 8%, Eupolyphaga Seu Steleophaga 10%, Os Draconis 9%, Pyritum 8%.Its preparation technology is identical with embodiment one.
41 kinds of pharmaceutical compositions for the treatment of cardiomyopathy of embodiment are to form by following components in weight percentage: Radix Notoginseng 37%, Moschus 2%, Radix Panacis Quinquefolii 17%, Olibanum 8%, Myrrha 9%, Eupolyphaga Seu Steleophaga 8%, Os Draconis 9%, Pyritum 10%.Its preparation technology is identical with embodiment one.
The pharmaceutical composition of embodiment kind on May Day treatment cardiomyopathy is to form by following components in weight percentage: Radix Notoginseng 38%, Moschus 1%, Radix Panacis Quinquefolii 15%, Olibanum 11%, Myrrha 8%, Eupolyphaga Seu Steleophaga 10%, Os Draconis 8%, Pyritum 9%.Its preparation technology is identical with embodiment one.
Claims (4)
1, a kind of pharmaceutical composition for the treatment of cardiomyopathy is characterized in that: it is following row raw materials by weight percent, makes according to following method:
Raw material is: Radix Notoginseng 35-40% Radix Panacis Quinquefolii 15-20% Olibanum 8-12% Myrrha 8-12%
Eupolyphaga Seu Steleophaga 8-12% Os Draconis 8-12% Pyritum 8-12% Moschus 1-2%
Method comprises: (1) extracts the volatile oil of Olibanum, Myrrha, and fixes with the beta-schardinger dextrin-inclusion, collects post-treatment and becomes extractum standby; (2) preparation Eupolyphaga Seu Steleophaga extracting solution is collected post-treatment and is become extractum standby; (3) repeatedly take Os Draconis water soluble ingredient and filtration, reconcentration becomes extractum standby: (4) preparation nature powdered copper concentrate; (5) Moschus after prepared extractum, natural powdered copper concentrate and the grinding is mixed and can make with the Radix Notoginseng of sterilization, Western pure extract powder.
2, a kind of pharmaceutical composition of treatment cardiomyopathy as claimed in claim 1 is characterized in that dosage form is a capsule.
3, a kind of pharmaceutical composition of treatment cardiomyopathy as claimed in claim 1, it is characterized in that: Olibanum wherein, Myrrha extract by following technology: Olibanum, Myrrha are ground into granule, do dissolution with solvents and be extracted into the colourless petroleum ether that in the water-bath ventilating kitchen, volatilizees again with petroleum ether, promptly get volatile oil, mixed inclusion with beta-schardinger dextrin-again and fix.
4, a kind of pharmaceutical composition of treatment cardiomyopathy as claimed in claim 1, it is characterized in that: Pyritum wherein is through following processes: get Pyritum and be popular in being fired to more than 560 ℃, the shortcake of quenching in the impouring rice vinegar immediately then, each 2 hours, repetition grinds to form impalpable powder until the gloss complete obiteration after drying again.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CNB001315161A CN1156287C (en) | 2000-10-24 | 2000-10-24 | A pharmaceutical composition for treating myocardial diseases |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CNB001315161A CN1156287C (en) | 2000-10-24 | 2000-10-24 | A pharmaceutical composition for treating myocardial diseases |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN1349812A CN1349812A (en) | 2002-05-22 |
| CN1156287C true CN1156287C (en) | 2004-07-07 |
Family
ID=4594693
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CNB001315161A Expired - Fee Related CN1156287C (en) | 2000-10-24 | 2000-10-24 | A pharmaceutical composition for treating myocardial diseases |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN1156287C (en) |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN101991665A (en) * | 2010-11-15 | 2011-03-30 | 张景红 | Composition for treating myocardial diseases, femoral head necrosis and tumor and preparation process thereof |
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN102008539B (en) * | 2010-11-18 | 2015-02-25 | 华侨大学 | Medicinal composition for treating diseases such as viral myocarditis and dilated cardiomyopathy and preparation process thereof |
| CN103285104B (en) * | 2013-05-14 | 2016-01-06 | 张景红 | A kind of have the Chinese medicine injection repairing myocardial damage effect |
-
2000
- 2000-10-24 CN CNB001315161A patent/CN1156287C/en not_active Expired - Fee Related
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN101991665A (en) * | 2010-11-15 | 2011-03-30 | 张景红 | Composition for treating myocardial diseases, femoral head necrosis and tumor and preparation process thereof |
Also Published As
| Publication number | Publication date |
|---|---|
| CN1349812A (en) | 2002-05-22 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN1240416C (en) | Medicine for curing hypertension and its preparation method | |
| CN100546615C (en) | Be used for the treatment of Chinese medicine composition of cerebrovascular and preparation method thereof | |
| CN111686147A (en) | Eucommia ulmoides extract and application thereof in treating osteoporosis | |
| CN1156287C (en) | A pharmaceutical composition for treating myocardial diseases | |
| CN1927293A (en) | Chinese medicine composition for treating skin burn and scald | |
| CN1695682A (en) | External use preparation for treating rheumatisma and bone injuries | |
| CN1785330A (en) | Medicine for treating high blood pressure and its preparation method | |
| CN1310664C (en) | Chinese medicine capsule for treating cardiac and cerebral vascular diseases and its production process | |
| CN111617193B (en) | Qinglong stopping particle | |
| CN1840170A (en) | Chinese proprietary medicine for treating cerebral thrombosis | |
| CN1692938A (en) | Compound traditional Chinese medicine for improving eyesight and its prepn. method | |
| CN101574426B (en) | Chinese patent medicament for treating liver diseases and method for preparing same | |
| CN1276764C (en) | Application of traditional Chinese medicine composition in preparation of medicine for treating iron-deficiency anemia | |
| CN1899385A (en) | Process for preparing Chinese medicine compound injection for treating chronic renal failure and use | |
| CN1857531A (en) | Recipe, preparing process and application of Chinese medicine preparation for treating diabetic retinopathy | |
| CN1272054C (en) | Medicine for treating diabetes and its preparing process | |
| CN109331067A (en) | The herbal mixture emplastrum for treating osteoarthritis | |
| CN1201811C (en) | Chinese medicine composition for treating myopia and preparing method thereof | |
| CN1317007C (en) | Pearl detoxifying oral liquid and preparing method tehreof | |
| CN1403113A (en) | Medicine for invigorating kidney, promoting blood circulation and promoting skeleton formation and its prepn | |
| CN1475261A (en) | Medicine for treating gastral cavity pain and its preparation method | |
| CN1287836C (en) | Chinese medicinal powder for treating diabetes and its production method | |
| CN1063077C (en) | Traditional Chinese medicine composition for lowering blood-lipid, and method for preparing same | |
| CN1242801C (en) | Medicinal composition for treating coronary heart disease and angine pectoris | |
| CN1853696A (en) | Medicine for treating coronary heart disease and preparation thereof |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| C06 | Publication | ||
| PB01 | Publication | ||
| C14 | Grant of patent or utility model | ||
| GR01 | Patent grant | ||
| C17 | Cessation of patent right | ||
| CF01 | Termination of patent right due to non-payment of annual fee |
Granted publication date: 20040707 Termination date: 20111024 |